Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc

Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc

Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc (CAS No. 894096-02-7) is a specialized cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs), which are innovative therapeutic agents designed for targeted cancer treatment. This compound plays a crucial role in delivering cytotoxic drugs specifically to cancer cells while minimizing damage to healthy tissues.

Chemical Properties

• Molecular Formula: C₃₈H₄₀N₂O₁₄
• Molecular Weight: 748.73 g/mol
• Density: 1.40 ± 0.1 g/cm³
• Boiling Point: 869.2 ± 65.0 °C
• Appearance: Off-white powder
• Storage Conditions: Should be stored in an inert atmosphere at temperatures between 2–8°C.

Structure and Functionality

The structure of Me-triacetyl-β-D-glucopyranuronate includes a glucopyranuronate moiety that is responsive to enzymatic activities, particularly those involving β-glucuronidase, which is overexpressed in many tumors. This enzymatic cleavability allows for the controlled release of the drug payload specifically within cancerous cells, enhancing the selectivity and efficacy of ADCs.

Advantages in ADC Development

• Stability: The triacetyl groups provide stability during systemic circulation, preventing premature drug release.
• Fmoc Group: The presence of the Fmoc (Fluorenylmethyloxycarbonyl) group allows for easy removal under mild conditions, facilitating the incorporation of various drug payloads. This feature is essential for customizing ADCs to target specific types of cancers effectively.

Applications

Me-triacetyl-β-D-glucopyranuronate-Ph-CH2OH-Fmoc is pivotal in advancing precision medicine by enabling highly targeted drug delivery systems. Its design supports the development of personalized therapies that can reduce adverse side effects while improving patient outcomes.

Researchers leverage this linker’s properties to create sophisticated ADCs that can adapt to the biological characteristics of specific tumors, thereby increasing treatment efficacy and safety. Overall, it serves as a critical component in the ongoing innovation within cancer therapeutics, enhancing the potential for improved patient care and outcomes.

Citations:

1. https://adc.bocsci.com/product/me-triacetyl-d-glucopyranuronate-ph-ch2oh-cas-894096-02-7-357944.html
2. https://www.chemsrc.com/en/cas/894096-02-7_1566181.html
3. https://www.apexbt.com/biochemical-reagent/signaling-pathways/me-triacetyl-b-d-glucopyranuronate-ph-ch2oh-fmoc-ba2486.html
4. https://pubchem.ncbi.nlm.nih.gov/compound/59816548
5. https://m.chemicalbook.com/ProductDetail_EN_me-triacetyl-d-glucopyranuronate-ph-ch2oh-fmoc_3183598.htm
6. https://www.medchemexpress.com/me-triacetyl-%CE%B2-d-glucopyranuronate-ph-ch2oh-fmoc.html
7. https://www.bocsci.com/product/me-triacetyl-d-glucopyranuronate-ph-ch2oh-cas-894096-02-7-357944.html
8. https://www.glpbio.com/kr/me-triacetyl-946-d-glucopyranuronate-ph-ch2oh-fmoc.html